Success Breeds Success

Bellicum's independent Clinical Advisory Board includes internationally renowned physicians with exemplary track records in the development of blockbuster drugs and biotherapeutics. Their collective resumes include leadership of pivotal trials for all three current FDA approved treatments for castrate resistant prostate cancer with a survival benefit, i.e. Taxotere® (docetaxel), Jevtana® (cabazitaxel), and Provenge® (sipuleucel-T). Jevtana® and Provenge® were approved in 2010.

• Philip W. Kantoff, M.D.
  Professor, Department of Medicine, Harvard Medical School; Chief, Division of Solid Tumor Oncology and Director of the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute.
• William K. Oh, M.D.
  Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; and Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine and Associate Director for Clinical Research, The Tisch Cancer Institute.
• Daniel P. Petrylak, M.D.
  Professor of Medicine, Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology and Co-Leader, Prostate Cancer in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.
• A. Oliver Sartor, M.D.
  Laborde Professor of Cancer Research and Medical Director, Tulane Cancer Center, Tulane University.
• Daniel D. Von Hoff, M.D., F.A.C.P.
  Physician-in-Chief, Senior Investigator, Translational Genomics Research Institute (TGen); Clinical Professor of Medicine, University of Arizona; and Chief Scientific Officer, Scottsdale Healthcare and US Oncology Research.